Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 33Breast Neoplasms 27Carcinoma, Non-Small-Cell Lung 22Triple Negative Breast Neoplasms 19Ovarian Neoplasms 19Lung Neoplasms 18Fallopian Tube Neoplasms 18Neoplasm Metastasis 15Squamous Cell Carcinoma of Head and Neck 12Endometrial Neoplasms 10Neoplasms 9Oropharyngeal Neoplasms 6Mouth Neoplasms 6Esophageal Neoplasms 6Cholangiocarcinoma 6Melanoma 5Colorectal Neoplasms 5Carcinoma 5Adenocarcinoma Of Esophagus 5Stomach Neoplasms 4Laryngeal Neoplasms 4Hypopharyngeal Neoplasms 4Esophageal Squamous Cell Carcinoma 4Carcinoma, Transitional Cell 4Anatomic Stage I Breast Cancer AJCC v8 4Pancreatic Adenocarcinoma 3Inflammatory Breast Neoplasms 3Head and Neck Neoplasms 3Gallbladder Neoplasms 3Carcinoma, Squamous Cell 3

Interventions

zolbetuximab 1Telemedicine 1Taxes 1Practice Guidelines as Topic 1Gemcitabine 1Counseling 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Pancreatic Adenocarcinoma × Taxes × 1 year × Clear all
NCT06576115 2025-11-05

Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer

Barbara Ann Karmanos Cancer Institute

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡